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ScienceDirectExpansion of a GGGGCC repeat in C9orf72 causes
amyotrophic lateral sclerosis, frontotemporal dementia, or a
combination of both. Bidirectional repeat transcripts sequester
RNA-binding proteins into nuclear RNA foci. The repeat is
translated into dipeptide repeat (DPR) proteins that are crucial
for repeat-induced toxicity. DPRs inhibit the proteasome and
sequester other proteins. These changes are accompanied by
widespread brain atrophy and subclinical cognitive impairment
before disease onset. Both repeat RNA and DPRs impair
nucleocytoplasmic transport and promote TDP-43
mislocalization and aggregation. Thus, repeat RNA and DPRs
may gradually trigger TDP-43 pathology and subsequent
region-specific neurodegeneration in a cascade similar to
amyloid-b peptide in Alzheimer’s disease. The key components
of the C9orf72 cascade are promising therapeutic targets in
different disease stages.
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Introduction
Frontotemporal dementia (FTD) and amyotrophic lat-
eral sclerosis (ALS) are two fatal neurodegenerative
diseases that overlap clinically, genetically and patho-
logically [1,2]. Degeneration of the frontotemporal
lobes results in behavioral disinhibition, dementia
and speech and language impairments, depending on
which regions are most affected. Loss of the upper and
lower motoneurons in the motor cortex and the spinal
cord causes progressive paralysis and ultimately respi-
ratory failure. Genetic and neuropathological findings
suggest that both diseases are opposite ends of a diseasewww.sciencedirect.com spectrum and many patients suffer from combined
symptoms. Neuropathologically, ALS and FTD are
classified depending on the key aggregating proteins.
TDP-43 inclusions are found in 60% of FTD and about
90% of ALS patients, specifically in neurons and glia in
the areas with the most severe neurodegeneration [3].
Rare TDP-43 mutations have been found to cause
predominantly ALS [4], but most inherited forms of
ALS or FTD with TDP-43 pathology are due to muta-
tions in several other genes, most commonly in GRN
(in FTD) and C9orf72 (in ALS and FTD) [5,6]. A
massive expansion of a GGGGCC repeat (with up to
several thousand repeats compared to fewer than 25 in
controls) upstream of the coding region of C9orf72
(Figure 1a) is the most common ALS/FTD causing
mutation among Caucasians [7–9]. Repeat expansions
cause equally likely ALS, FTD or a mixture of both
and are found in 5–40% of familial ALS and FTD cases
and in 5% seemingly sporadic patients [10,11].
Pathomechanisms
Several pathomechanisms have been proposed for
C9orf72 ALS and FTD that may act in concert. These
include: Firstly, haploinsufficiency; secondly, RNA tox-
icity, and finally, toxicity of highly unusual protein depos-
its.
Many studies show reduced mRNA expression in
C9orf72 ALS/FTD cases [7–9] that was recently con-
firmed on the C9orf72 protein level [12], suggesting
haploinsufficiency as a cause of ALS/FTD. However,
the physiological function of the C9orf72 protein is
poorly understood and neuron specific knockout mice
develop no disease like pathology [13] making it unlikely
that haploinsufficiency significantly contributes to the
disease mechanism.
The presence of nuclear foci of the repeat RNA
(Figure 1b) suggests that sense and antisense transcripts
of the repeat sequester specific RNA-binding proteins,
which may profoundly alter RNA-metabolism. Several
(ggggcc)n and (ccccgg)n interacting proteins (lower case
denotes RNA) have been identified in vitro, including
hnRNPA3 [14], SRSF2, hnRNP H1/F, ALYREF [15],
ADARB2 [16] and Nucleolin [17].
Pathologically, C9orf72 mutation cases show specific
star-shaped or dot-like TDP-43 negative, p62-positive
cytoplasmic inclusions, which are not found in other
ALS/FTD cases [18]. The core components of theseCurrent Opinion in Neurobiology 2016, 36:99–106
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Genomic structure of C9orf72 and key pathological findings. (a) Depiction of the three main transcript of C9orf72. The GGGGCC-repeat expansion
(about 100–5000 repeats compared to <30 repeat in controls) is either located upstream of the coding region (orange), in the promoter region
(isoform V1) or in the first intron (isoforms V2 and V3). V1 and V3 encode the same 54 kDa isoform, while V2 encodes a C-terminally truncated
25 kDa isoform. The sense transcript (ggggcc RNA repeat in lower case) is translated in all three reading frames into abundant DPR proteins. (b)
RNA foci formed by the sense strand (arrow) are detectable by in situ hybridization in the nucleus. (c) Specific antibodies detect DPR inclusions
derived from non-ATG translation of sense and antisense repeat transcripts in all reading frames.inclusions are derived from unconventional translation
of the intronic repeat RNA in all reading frames into
five aggregating dipeptide repeat (DPR) proteins
(Figure 1a,c) [19,20,21–23]. Virtually all TDP-43
negative inclusions contain poly-GA. The other DPR
species coaggregate to a variable extent in these inclu-
sions. Poly-GP and poly-GR are found in about half of
the aggregates, while the antisense transcript-derived
poly-PA and poly-PR are much rarer.Current Opinion in Neurobiology 2016, 36:99–106 Repeat-associated non-ATG (RAN) translation was first
discovered for (cag)n expansions and is thought to involve
hairpin formation of the repeat mRNA [24]. Recently,
RAN translation of an expanded (cgg)n repeat was also
observed in fragile X tremor ataxia syndrome [25]. It is
still unclear how repetitive RNA hairpins can overcome
the tight control mechanisms during translation initiation,
but interfering with the secondary structure has been
shown to reduce translation of the C9orf72 repeat [26].www.sciencedirect.com
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from cellular and animal models and findings from neuro-
pathological and clinical studies. Furthermore, we unify
these findings into a pathological cascade with surprising
similarities to the amyloid cascade in Alzheimer’s disease
(AD).
A major role of C9orf72 loss of function in
ALS/FTD is unlikely
Although reduction of C9orf72 transcripts has been de-
scribed already in the initial reports of the C9orf72 repeat
expansion (and widely replicated afterwards), it remains
unclear whether haploinsufficiency contributes to
C9orf72 pathogenesis. Data on promoter hypermethyla-
tion even suggest that reduced C9orf72 expression is
neuroprotective, because methylation correlates with pro-
longed survival [27].
Neuron specific conditional knockout of C9orf72 in mice
leads to an unexplained weight loss, but does not cause
motor symptoms, TDP-43 pathology, neurodegeneration,
neuroinflammation or premature death [13], although this
does not exclude a non-neuronal component of haploin-
sufficiency. Moreover, sustained reduction of C9orf72
expression by antisense oligonucleotides (ASO) in mouse
brain did not result in ALS/FTD like symptoms [28].
Thus, C9orf72 loss of function does not seem to cause
TDP-43 associated neurodegeneration and is unlikely to
be the main cause of ALS/FTD.
To fully address a possible loss of function component, a
better understanding of the C9orf72 function is crucial.
Unfortunately, antibodies detecting endogenous C9orf72
are notoriously difficult to generate, which may be due to
the low endogenous expressions levels. C9orf72 protein
levels are about 200-fold lower than the levels of TDP-43
and FUS in motor neurons and various cell lines [29].
Homology searches identified a putative DENN (Differ-
entially Expressed in Normal and Neoplasia) domain in
C9orf72 suggesting it acts as a guanine nucleotide ex-
change factor (GEF) for small GTPases, particularly within
the Rab protein family [30]. Indeed, partial colocalization
of C9orf72 with Rab1/5/7/11 endo-lysosomes was reported,
which suggests that C9orf72 might regulate protein degra-
dation and autophagy [31]. In contrast, antibodies to the
short isoform have been reported to label the nuclear
envelop in healthy controls and the plasma membrane
in ALS cases with or without C9orf72 mutation indicating
a general defect in nuclear trafficking in ALS [32] which
may be interesting in regard to the nuclear transport
deficiencies recently reported as a pathological conse-
quence of C9orf72 repeat expansions (see below).
Gain of function models resemble patient
pathology best
Many groups have reported toxic gain of function of the
C9orf72 repeat expansion in cellular and animal modelswww.sciencedirect.com that to various degrees invoke either DPR, RNA toxicity,
or both. iPSC-derived neurons from C9orf72 patients
consistently show RNA foci, but lack abundant compact
DPR inclusions, while DPR protein expression is often
detectable at low level [16,33–35]. Most likely inclusion
formation is a slow process due to inefficient non-ATG
translation of the DPR proteins. Several groups reported
subtle changes in gene expression in patient derived
fibroblasts and neurons, but the different studies show
little overlap [16,28,35]. Neurons carrying the repeat
expansion are initially hyperexcitable [16] and become
hypoexcitable later in development [34,35] which may
lead to the functional inactivation of motoneurons before
cell death. In patient derived neurons, ASOs targeting the
repeat or the C9orf72 gene reduce RNA foci surprisingly
without affecting poly-GP expression and restored nor-
mal gene expression arguing for predominant RNA tox-
icity [16], although this may also be explained by a long
half-life of poly-GP. Similarly, ASOs have been shown to
inhibit RNA foci formation in patient fibroblasts, but did
not correct altered gene expression in this case [28].
To dissect the role of RNA and protein toxicity, several
groups expressed endogenous ggggcc-repeat sequence or
used ATG-initiated synthetic genes where the ggggcc-
repeat was replaced by alternative codons for expression
of individual DPR proteins in cellular models, suggesting
poly-GA is the most aggregation prone DPR protein
within cells [21,36–40]. Nearly all reports observed
p62-positive cytoplasmic inclusions like those found in
C9orf72 patients only upon poly-GA expression [21,36–
39]. In many reports this was associated with toxicity.
Poly-GA neurotoxicity has been attributed to impaired
function of the ubiquitin proteasome system and seques-
tration of Unc119, a protein regulating the trafficking of
myristoylated cargo proteins [36–38]. Two inhibitors of
ER stress, salubrinal and TUDCA, were able to rescue
poly-GA toxicity [37]. In contrast, poly-GR and poly-PR
expression typically resulted in nucleolar inclusions and
also induced toxicity [38,39,41]. While poly-GR and poly-
PR toxicity was stronger than poly-GA toxicity in many
systems, we could not detect such nucleolar poly-GR/PR
inclusions in patient tissue using monoclonal antibodies
[42]. Poly-GR/PR may interfere with RNA metabolism
and protein synthesis by directly binding RNA, particu-
larly in the nucleolus through repetitive arginine residues
[39,41]. Importantly, co-expression of poly-GA and poly-
GR recruits poly-GR into cytoplasmic inclusions and
partially rescues its toxicity in a model with predominant-
ly diffuse cytoplasmic GR80 expression [43] indicating
that the toxicity of poly-GR depends is on its localization.
Sense strand repeat expression without start codon had
little effect in most cellular models [36,39], while anti-
sense repeat expression has been linked to toxicity [21].
In Drosophila, however, expression of ggggcc-repeats of
increasing length causes degeneration in the eye that isCurrent Opinion in Neurobiology 2016, 36:99–106
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completely prevented by stop codons interspaced in the
repeat [44]. While expression of poly-GR and poly-PR
from synthetic genes throughout the nervous system
caused early lethality, poly-GA expression still signifi-
cantly shortened the life span of transgenic flies. In
another report, diffuse cytoplasmic GR80 expression spe-
cifically in the fly wing causes a classic notching pheno-
type that can be rescued by expressing the membrane-
tethered transcription factor Notch [43]. At least in flies,
cytoplasmic ggggcc-repeat RNA derived from poly-A
tailed expression is far more toxic than nuclear repeat
RNA derived from intronic expression, which has been
attributed to enhanced DPR expression of the RNA
exported from the nucleus [45].
Three recent reports found that modulation of nuclear
transport in flies and yeast suppresses toxicity of repeat
RNA and/or poly-GR/PR [46,47,48]. Expression of
the sense repeat in the fly eye induced toxicity with
partial mislocalization of the fly TDP-43 homology
(TBPH) protein, although poly-GR and poly-GP ex-
pression was not detected in this model [46]. The
sense repeat RNA binds to and inhibits RanGAP and
thus disturbs the nucleocytoplasmic Ran gradient criti-
cal for the localization of many other proteins and
RNAs, because only RanGDP but not RanGTP is
imported into the nucleus. Enhancing nuclear import
using overexpression of RanGAP or Importin-a sup-
presses neurodegeneration. Interestingly, RanGAP nor-
mally shows smooth perinuclear staining whereas
RanGAP aggregates are found along the nuclear enve-
lope in iPSC derived neurons and tissue from C9orf72
mutation cases [46]. Moreover, in an unbiased screen
in ggggcc-expressing flies Freibaum and colleagues
identified 18 enhancers and suppressors that encode
components of the nuclear pore complex (NPC) [47].
This group observed poly-GP and poly-GR, but no
poly-GA expression. Boosting nuclear import by ex-
pression of karyopherins also rescues poly-PR toxicity
in yeast suggesting that the ggggcc-repeat RNA and
poly-GR/PR cause toxicity by disrupting nucleocyto-
plasmic transport [48]. Interestingly, nucleocytoplas-
mic transport seems to be affected in ALS patients
without C9orf72 mutation and may therefore be a
common feature of ALS [32,49]. In line with that,
ALS causing mutations affect the PY-NLS of FUS
and lead to its accumulation within the cytosol and
its subsequent aggregation [50].
The best mouse model so far is based on AAV-mediated
(ggggcc)66 expression [51
]. Six months after neonatal
intracerebroventricular injection, nuclear RNA foci and
intranuclear and cytoplasmic poly-GA/GP/GR inclusions
were detected together with diffuse nuclear poly-GP and
diffuse cytoplasmic poly-GR. These mice show mild
neuronal loss and deficits in the Rota-Rod assay, suggestingCurrent Opinion in Neurobiology 2016, 36:99–106 impaired motor coordination or balance. Importantly, this
is the first C9orf72 model displaying prominent TDP-43
aggregates and thus most closely resembles C9orf72 ALS/
FTD patients. Cells with TDP-43 aggregates always had
visible RNA foci, while poly-GA inclusions were present in
75% of these cells. Similarly, we recently generated a cell
culture model by high-level expression of a (ggggcc)80
repeat without start codons that co-expresses all DPRs
and showed cytoplasmic redistribution of TDP-43 (Mori
et al., unpublished).
The first cellular and animal models clearly highlight the
importance of toxic gain of function as the origin of TDP-
43 aggregation and neurodegeneration. Particularly, poly-
GR/PR and to a lesser extent poly-GA are neurotoxic in
vitro and in vivo, but only aggregates in the poly-GA
models resemble the inclusions found in patients. It will
be critical to determine, which of the mechanisms of RNA
and DPR toxicity seen in model systems contribute to
pathogenesis in patients.
Lack of spatial correlation of DPR deposits
with TDP-43 pathology and
neurodegeneration
The distribution of sense and antisense RNA foci and
interacting proteins has not been rigorously studied in
large cohorts of ALS and FTD cases. One possible reason
might be that these tiny structures are only visible in large
magnifications and would require great effort for quanti-
tative analysis of several brain regions in many patients. A
recent study found that only antisense, but not sense
RNA foci correlated with pathological nuclear clearance
of TDP-43 in motoneurons [52].
Regardless of clinical or neuropathological diagnosis,
poly-GA/GP/GR inclusions are widespread throughout
the neocortex, hippocampus, cerebellum and thalamus
and rare in the spinal cord including motor neurons
[23,42,53,54,55]. Thus, DPR distribution is not spa-
tially correlated with the areas of most prominent
neurodegeneration in ALS and FTD cases. Interesting-
ly, the distribution of amyloid plaques also poorly
correlates with the neurodegeneration and clinical pro-
gression in AD cases [56]. However, recently some
clinical correlates of DPR deposits have been found
in C9orf72 mutant cohorts. Higher poly-GA load is
associated with earlier age of onset [54]. Cases with
FTD with or without additional signs of motoneuron
disease show more cerebellar poly-GA inclusions than
cases with pure motoneuron disease [42]. Poly-PR has
been reported to preferentially aggregate in motor
neurons [52], but this has not been confirmed by us
and others [42,55]. Several FTD cases with abundant
DPR but without TDP-43 pathology have been identi-
fied, strongly arguing that DPR pathology contributes
at least to the early symptoms of C9orf72 patients
[19,57,58].www.sciencedirect.com
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pathology is highly correlated with areas of neurodegen-
eration and clinical symptoms [3,53]. Thus, TDP-43
mislocalization and/or aggregation are the most likely
effectors of C9orf72 repeat associated toxicity, although
a causal relation is not formally proven and the mecha-
nistic link is not fully resolved. Interestingly, pathogenic
TDP-43 mutations cause predominantly regional TDP-
43 pathology similar to sporadic ALS/FTD cases indicat-
ing that motoneurons and the frontotemporal cortex are
especially susceptible to cytoplasmic TDP-43 aggrega-
tion [59]. Therefore, Dormann and Haass formulated a
multiple hit hypothesis where additional stressors must
induce the irreversible deposition of TDP-43 following
initial cytoplasmic mislocalization [1]. We speculate that
DPR proteins and repeat RNA are such stressors that
promote TDP-43 pathology in C9orf72 patients.
Cross-sectional analysis of C9orf72 patients
reveals widespread brain atrophy and early
cognitive deficits
Recent clinical data may help to reconcile the conflict-
ing findings on DPR toxicity in model systems andFigure 2
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genic mutations revealed changes in biomarkers, imag-
ing parameters and cognitive tests many years
before clinical dementia and established the concept
of prodromal disease stages [60]. Similarly, the GENFI
consortium analyzed presymptomatic changes in indi-
viduals carrying FTD-causing mutations in C9orf72,
GRN or MAPT and normalized the data to the average
age of onset within each family [61]. While all carriers
showed impairment in neuropsychological tests several
years before developing clinical FTD/ALS, C9orf72
carriers showed detectable impairment 5–15 years ear-
lier than the GRN or MAPT patients. Moreover, while
volumetric imaging data support discrete atrophy in the
insula and temporal cortex 5–10 years before the
expected age of onset independent of the mutation,
C9orf72 patients showed widespread atrophy in the
neocortex and thalamus already 20–25 years before
the expected disease onset. Since TDP-43 pathology
is largely limited to the frontotemporal cortex and the
motor cortex, the clinical findings argue for an early role
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cases.
An amyloid-like cascade model of C9orf72
pathogenesis
Together these findings led us to postulate a cascade
hypothesis for C9orf72 associated ALS/FTD in approxi-
mate analogy to the amyloid cascade hypothesis for
Alzheimer’s disease [56,62,63]. Increased production, ag-
gregation or failure of clearance of the amyloid b-peptide
(Ab) is the most likely initial trigger of the disease
(Figure 2a). Accumulation of soluble Ab species, subtle
synaptic dysfunction and insoluble Ab plaques induce an
inflammatory response, which may result in microglial
dysfunction and an early cognitive dysfunction in neuro-
psychological tests [60]. Then, a misbalance of kinases
and phosphates boosts abnormal phosphorylation of tau
and its subsequent aggregation and deposition in tangles.
Tau aggregates or oligomers further impair synaptic func-
tion and cause neuronal loss by incompletely defined
mechanisms. Importantly, Ab pathology arises decades
before the onset of dementia in the neocortex and then
spreads centripetally towards the brain stem. By the time
of diagnosis Ab pathology has reached a plateau and
poorly correlates with disease progression similar to
DPR pathology in ALS/FTD. In contrast, the progression
of Tau pathology from the (trans)entorhinal cortex to the
neocortex correlates well with the clinical progression of
dementia.
In line with Ab plaques, we postulate that DPR proteins
and toxic RNA may trigger a deadly cascade decades
before clinical symptoms occur. Most likely, several cell
autonomous and non-cell autonomous mechanisms act in
concert. Sequestration of RNA-binding proteins, im-
pairment of nuclear import and transcriptional alterations
may lead to TDP-43 hyperphosphorylation, mislocaliza-
tion and reduced excitability of neurons. DPR proteins
may promote TDP-43 aggregation by inhibiting the
proteasome and further altering RNA metabolism and
nuclear transport. This is in line with the multiple hit
model for FUS and TDP-43 aggregation in ALS/FTD [1].
We speculate that DPR aggregates could induce neuroin-
flammation which may further enhance TDP-43 aggre-
gation. Neuronal cell death could then be induced by
cytosolic accumulation of abnormally phosphorylated
TDP-43 in analogy to abnormally phosphorylated tau.
Thus, the lack of correlation of Ab plaques and DPR
inclusion density with neurodegeneration may be
explained by triggering a slow cascade before clinical
disease onset that can later sustain itself independent
of its trigger as it has been postulated for AD [56].
According to our cascade model, three strategic points
appear most suited for therapeutic intervention. First,
preventing initiation of the disease cascade right at the
top, for example, by enhancing repeat RNA degradationCurrent Opinion in Neurobiology 2016, 36:99–106 or preventing its translation using ASOs [16,28]. Sec-
ond, preventing the conversions from presymptomatic to
symptomatic stage by targeting DPR or RNA toxicity to
block initiation of TDP-43 mislocalization, for example,
by boosting DPR degradation or by modulating the
structure of the repeat RNA-repeat or by restoring nuclear
transport [26,46,47,48]. Third, targeting common
downstream mechanisms not limited to ALS and FTD
cases with C9orf72 mutation, for example, by inhibiting
TDP-43 aggregation and toxicity or modulating inflam-
mation. This concept highlights the need for combination
of different drugs in the prodromal and later stages of
C9orf72 ALS/FTD.
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